Phase I Multi-Center Study of Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Vulvovaginal cancer
- Focus Adverse reactions
- 21 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 09 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
- 06 Mar 2018 New trial record